NCT04039204View on ClinicalTrials.gov

Elagolix for Fertility Enhancement Clinical Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

August 9, 2023

Study Completion Date

August 9, 2023

Conditions
EndometriosisUnexplained Infertility
Interventions
DRUG

Elagolix

This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET

DRUG

Ortho Cyclen

Oral contraceptive prescribed by physician.

Trial Locations (1)

27157

Wake Forest Univesity Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

Stanford University

OTHER

lead

Wake Forest University Health Sciences

OTHER